Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.50 |
| ▸ | CASP3 | P42574 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | GLS | O94925 | 1/20 | 0.46 |
| ▸ | TACR1 | P25103 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5993629 | 0.86 | EPHX2 (0.52) | EPHX2CASP3MAPTGLSHPGD | |
| SCHEMBL6385132 | 0.82 | EPHX2 (0.64) | EPHX2MAPTGLS | |
| SCHEMBL13014828 | 0.81 | POLB (0.45) | EPHX2MAPTHPGDPOLB | |
| SCHEMBL11083024 | 0.76 | EPHX2 (0.59) | EPHX2MAPTGLSHPGDTDP1 | |
| SCHEMBL10305728 | 0.76 | RECQL (0.57) | HPGDL3MBTL1 | |
| SCHEMBL7674546 | 0.75 | POLB (0.67) | MAPTHPGDPOLB | |
| SCHEMBL11085609 | 0.75 | EPHX2 (0.58) | EPHX2MAPTGLSHPGDTDP1 | |
| Hydrochloric Acid SCHEMBL32690605 | 0.73 | LMNA (0.44) | — | |
| Hydrochloric Acid SCHEMBL27634849 | 0.73 | POLB (0.65) | MAPTHPGDPOLB | |
| SCHEMBL11087924 | 0.73 | EPHX2 (0.64) | EPHX2MAPTGLS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9278922-B2 | Anti-viral compounds | ABBVIE INC. (US) | 2016-03-08 | — | — | US | disclosed |
| US-20100317568-A1 | Anti-Viral Compounds | Abbott Labaoratories (US) | 2010-12-16 | — | — | US | disclosed |
| US-20100267634-A1 | Anti-Viral Compounds | Abbott Labaoratories (US) | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317568-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | EPHX2 3893/4885CASP3 827/4885MAPT 2833/4885 |
| US-20100267634-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | EPHX2 3893/4885CASP3 827/4885MAPT 2833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.